Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.

Status:
Not yet recruiting

Trial end date:
2034-07-01

Target enrollment:

Participant gender:

To learn if regorafenib can help to control the disease.

Phase 2

M.D. Anderson Cancer Center

Bayer